A Phase 2 interventional study of Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID) and Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID) in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V. — 2 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Laboratorios Sophia S.A de C.V..
Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 2, and was the 9th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V. are open now. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V.
Ages 18+ · Healthy volunteers
Laboratorios Sophia S.A de C.V.
Ages 18+ · Healthy volunteers
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 34 across the 13 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
1 of the studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06379685Laboratorios Sophia S.A de C.V.Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire. Three dosage schemes of topical ophthalmic application of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%; preservative free) are to be evaluated in patients diagnosed with mild to severe dry eye. Each group will be exposed to one of the following administration schemes: 1 drop bis in die (BID), 1 drop quater in die (QID), or 1 drop six times per day; instillation will take place in both eyes (OU).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presenting a mild to moderate dry eye disease diagnosis, defined as:
OSDI score between 13 and 32, plus one of the following:
Exclusion Criteria:
Diagnosis of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) one drop twice a day (BID) in both eyes (OU) during 30 days.
Drug: Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID)
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) one drop four times a day (QID) in both eyes (OU) during 30 days.
Drug: Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID)
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
Drug: Sodium Hyaluronate Ophthalmic 0.4% Six times per day
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
Also known as: PRO-037, Lagricel® Ofteno
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
Also known as: PRO-037, Lagricel® Ofteno
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
Also known as: PRO-037, Lagricel® Ofteno
Change in Ocular Surface Disease Index (OSDI)
OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.
Time frame: Basal Visit (BV) (day 0) and Final Visit (FV) (day 31+1,).
Incidence of Adverse Events (AE)
Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution and whether it was considered related or not to the investigation products.
Time frame: Up to Day 33 (+ 1) (safety call).
Change in Tear Break-up Time (BUT)
After application of fluorescein stain, using a slit lamp and its cobalt blue filter, the time elapsed after instructing the patient to blink 1 or 2 times and the appearance of dry spots on the ocular surface will be counted and reported as BUT. Normally, this parameter is ≥ 10 seconds.
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Change in Conjunctival and Corneal Staining With Lissamine Green
The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Change in Conjunctival and Corneal Staining With Fluorescein
The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Change in Conjunctival Hyperemia
Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (III), and Severe (IV).
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Incidence of Chemosis
Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. This evaluation will be made taking in consideration the counts of "absent" seen per counts of eyes and per visit.
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Change in Best Corrected Visual Acuity (BCVA)
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. The normal score for a VA is 20/20.This score is expressed in decimal (i.e. 1.0) format. In decimal format, a lower number is a worse outcome.
Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Change in Intraocular Pressure (IOP)
Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP will be evaluated. Normal values are considered between 10 and 21 mmHg.
Time frame: BV (day 0, baseline visit), V1 (day 15±1, first follow-up visit), and FV (day 31+1, final visit).
| Milestone | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Started | 47 | 47 | 47 |
| Completed | 45 | 45 | 46 |
| Not completed | 2 | 2 | 1 |
OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.
| score on a scale | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV | 25.8 ± 4.9 | 25.8 ± 4.7 | 24.8 ± 5.3 |
| FV | 12.8 ± 6.0 | 12.2 ± 5.8 | 11.9 ± 6.9 |
Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution and whether it was considered related or not to the investigation products.
| adverse events | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Related and unexpected AE | 24 | 17 | 22 |
| Related and expected AE | 11 | 9 | 7 |
| Non-related AE | 21 | 15 | 16 |
After application of fluorescein stain, using a slit lamp and its cobalt blue filter, the time elapsed after instructing the patient to blink 1 or 2 times and the appearance of dry spots on the ocular surface will be counted and reported as BUT. Normally, this parameter is ≥ 10 seconds.
| seconds | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV | 6.1 ± 2.2 | 6.4 ± 2.1 | 6.3 ± 2.3 |
| V1 | 9.1 ± 3.3 | 9.0 ± 2.5 | 9.2 ± 2.8 |
| FV | 9.7 ± 3.4 | 10.1 ± 3.2 | 11.0 ± 4.3 |
The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).
| Eyes (right) | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV Conjunctival and corneal staining with lissamine green : Absent (0) | 15 | 15 | 14 |
| BV Conjunctival and corneal staining with lissamine green : Minimal(I) | 21 | 19 | 21 |
| BV Conjunctival and corneal staining with lissamine green : Mild (II) | 9 | 10 | 10 |
| BV Conjunctival and corneal staining with lissamine green : Moderate (III) | 0 | 1 | 1 |
| V1 Conjunctival and corneal staining with lissamine : Absent (0) | 28 | 30 | 31 |
| V1 Conjunctival and corneal staining with lissamine : Minimal(I) | 15 | 14 | 15 |
| V1 Conjunctival and corneal staining with lissamine : Mild (II) | 2 | 1 | 0 |
| V1 Conjunctival and corneal staining with lissamine : Moderate (III) | 0 | 0 | 0 |
| FV Conjunctival and corneal staining with lissamine : Absent (0) | 40 | 36 | 43 |
| FV Conjunctival and corneal staining with lissamine : Minimal(I) | 5 | 9 | 3 |
| FV Conjunctival and corneal staining with lissamine : Mild (II) | 0 | 0 | 0 |
| FV Conjunctival and corneal staining with lissamine : Moderate (III) | 0 | 0 | 0 |
The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).
| Eyes (right) | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV Conjunctival and corneal staining with fluorescein : Absent (0) | 13 | 11 | 11 |
| BV Conjunctival and corneal staining with fluorescein : Minimal (I) | 20 | 22 | 25 |
| BV Conjunctival and corneal staining with fluorescein : Mild (II) | 12 | 11 | 9 |
| BV Conjunctival and corneal staining with fluorescein : Moderate (III) | 0 | 1 | 1 |
| V1 Conjunctival and corneal staining with fluorescein : Absent (0) | 20 | 23 | 28 |
| V1 Conjunctival and corneal staining with fluorescein : Minimal (I) | 19 | 21 | 17 |
| V1 Conjunctival and corneal staining with fluorescein : Mild (II) | 6 | 1 | 1 |
| V1 Conjunctival and corneal staining with fluorescein : Moderate (III) | 0 | 0 | 0 |
| FV Conjunctival and corneal staining with fluorescein : Absent (0) | 28 | 30 | 36 |
| FV Conjunctival and corneal staining with fluorescein : Minimal (I) | 16 | 15 | 10 |
| FV Conjunctival and corneal staining with fluorescein : Mild (II) | 1 | 0 | 0 |
| FV Conjunctival and corneal staining with fluorescein : Moderate (III) | 0 | 0 | 0 |
Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (III), and Severe (IV).
| Eyes (right) | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV: Normal (0) | 11 | 6 | 7 |
| BV: Very Mild (I) | 14 | 21 | 19 |
| BV: Mild (II) | 17 | 17 | 19 |
| BV: Moderate (III) | 3 | 1 | 1 |
| V1: Normal (0) | 16 | 18 | 14 |
| V1: Very Mild (I) | 21 | 23 | 28 |
| V1: Mild (II) | 8 | 4 | 4 |
| V1: Moderate (III) | 0 | 0 | 0 |
| FV: Normal (0) | 20 | 21 | 24 |
| FV: Very Mild (I) | 24 | 24 | 21 |
| FV: Mild (II) | 1 | 0 | 1 |
| FV: Moderate (III) | 0 | 0 | 0 |
Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. This evaluation will be made taking in consideration the counts of "absent" seen per counts of eyes and per visit.
| Eyes (right) | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV: Absent | 45 | 45 | 46 |
| V1: Absent | 45 | 45 | 46 |
| FV: Absent | 45 | 45 | 46 |
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. The normal score for a VA is 20/20.This score is expressed in decimal (i.e. 1.0) format. In decimal format, a lower number is a worse outcome.
| decimal score | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV | 0.97 ± 0.08 | 0.99 ± 0.04 | 0.98 ± 0.04 |
| V1 | 0.98 ± 0.07 | 0.99 ± 0.02 | 0.99 ± 0.02 |
| FV | 0.97 ± 0.08 | 0.99 ± 0.03 | 0.99 ± 0.04 |
Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP will be evaluated. Normal values are considered between 10 and 21 mmHg.
| mmHg | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| BV | 13.7 ± 2.6 | 14.5 ± 2.8 | 14.4 ± 2.5 |
| V1 | 13.6 ± 2.4 | 14.1 ± 2.3 | 13.6 ± 2.1 |
| FV | 13.6 ± 2.5 | 13.8 ± 2.2 | 13.7 ± 2.1 |
Collected over From day 1 (basal visit) to the safety call on day 33 (±1 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | 0/47 (0%) | 1/47 (2.1%) | 22/47 (46.8%) |
| Group 2 | 0/47 (0%) | 0/47 (0%) | 22/47 (46.8%) |
| Group 3 | 0/47 (0%) | 0/47 (0%) | 22/47 (46.8%) |
| Event | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| reaction to immunizationImmune system disorders | 1/47 | 0/47 | 0/47 |
| Event | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Irritation in the area of instillationEye disorders | 15/47 | 14/47 | 13/47 |
| abnormal sensation in the eyeEye disorders | 6/47 | 3/47 | 4/47 |
| Abormal ocular sensationEye disorders | 6/47 | 3/47 | 4/47 |
| PruritusEye disorders | 2/47 | 2/47 | 5/47 |
| Blurred visionEye disorders | 5/47 | 4/47 | 4/47 |
| presence of product residueProduct Issues | 2/47 | 5/47 | 4/47 |
| HeadacheNervous system disorders | 2/47 | 0/47 | 4/47 |
| Foreign body sensation in the eyeEye disorders | 4/47 | 3/47 | 2/47 |
| TearingEye disorders | 4/47 | 2/47 | 1/47 |
| Ocular hyperaemiaEye disorders | 2/47 | 0/47 | 1/47 |
| Age, Categorical(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 45 | 45 | 44 | 134 |
| >=65 years | 2 | 2 | 3 | 7 |
| Age, Continuous(years) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 14.6 | 38.9 ± 13.3 | 36.5 ± 14.9 | 37.95 ± 14.21 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Female | 32 | 31 | 28 | 91 |
| Male | 15 | 16 | 19 | 50 |
| Race and Ethnicity Not Collected(Participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(participants) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Mexico | 47 | 47 | 47 | 141 |
| Brake up time of the tear film(seconds) | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Mean | 9.1 ± 3.3 | 9.0 ± 2.5 | 9.2 ± 2.8 | 9.0 ± 3.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Jun 2022, 5 months.
Results were first posted in Mar 2026, 3 years 8 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 5 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Sophia S.A de C.V. →